急性髓系白血病白血病干细胞概念25年:击中移动靶点
该综述回顾白血病干细胞(LSC)概念提出25年来的进展,指出尽管分子分型和靶向LSC的研究大量涌现,但LSC的识别与定义在个体患者层面仍因克隆内异质性而困难,尚未充分转化为AML临床获益,并提出未来研究方向。
要点
- LSC概念源于25年前将AML细胞移植入免疫缺陷小鼠的实验。
- 初始LSC频率估计为1:250 000个白血病细胞,提示临床转化困难。
- LSC识别与定义受克隆内异质性限制,尚未在临床常规实现。
核心结论
- LSC的重要数据尚未在临床环境中充分实现,需进一步研究以转化为AML患者的实时获益。
研究设计与样本
- 本篇为聚焦临床的综述,基于LSC概念提出25年来的实验与分子研究文献进行论述。
主要发现
- 25年前实验显示AML患者中一小部分细胞可 adoptive 转移至免疫缺陷小鼠,初始频率估计为1:250 000个白血病细胞。
- 随着数百个AML基因组测序完成,文献报道不同分子异常对LSC的特异性以及靶向LSC相对于正常造血干祖细胞的选择性。
临床怎么用
- 在个体患者层面识别和定义LSC需考虑克隆内异质性,目前尚不能常规用于临床决策。
局限性
- LSC在个体患者层面的识别与定义存在困难,尤其受克隆内异质性影响。
- 重要LSC数据尚未在临床环境中充分实现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The concept of leukaemic stem cells (LSCs) was experimentally suggested 25 years ago through seminal data from John Dick's group, who showed that a small fraction of cells from acute myeloid leukaemia (AML) patients were able to be adoptively transferred into immunodeficient mice. The initial estimation of the frequency was 1:250 000 leukaemic cells, clearly indicating the difficulties ahead in translating knowledge on LSCs to the clinical setting. However, the field has steadily grown in interest, expanse and importance, concomitantly with the realisation of the molecular background for AML culminating in the sequencing of hundreds of AML genomes. The literature is now ripe with contributions describing how different molecular aberrations are more or less specific for LSCs, as well as reports showing selectivity in targeting LSCs in comparison to normal haematopoietic stem and progenitor cells. However, we argue here that these important data have not yet been fully realised within the clinical setting. In this clinically focused review, we outline the difficulties in identifying and defining LSCs at the individual patient level, with special emphasis on intraclonal heterogeneity. In addition, we suggest areas of future focus in order to realise the concept as real-time benefit for AML patients.
引用
- Hokland P, Woll PS, Hansen MC, et al. The concept of leukaemic stem cells in acute myeloid leukaemia 25 years on: hitting a moving target. Br J Haematol. 2019. PMID: 31372979. doi:10.1111/bjh.16104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。